Literature DB >> 11698140

Low cerebrospinal fluid beta-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment.

M Sjögren1, M Gisslén, E Vanmechelen, K Blennow.   

Abstract

CSF-A beta 42 may be a marker of Alzheimer's disease (AD). A decreased level of CSF-A beta 42 is consistently found in AD and has been suggested to be related to the deposition of amyloid plaques in the brain. However, low CSF-A beta 42 levels have also been found in disorders devoid of plaques, for instance Creutzfeldt-Jakob disease. To examine if the level of A beta 42 in CSF is related to inflammatory processes, we studied CSF-A beta 42 levels in eight patients with acute purulent bacterial meningitis, 10 patients with acute viral meningitis and 18 age-matched controls. In acute purulent bacterial meningitis, the CSF-A beta 42 level was markedly reduced (28% of that in controls, P<0.0001), whereas no change was found in viral meningitis. After successful treatment of bacterial meningitis, the CSF-A beta 42 level increased (P<0.05 compared to baseline) and did no longer differ from that in controls (ns). The decrease could not be explained by interference with high protein levels, since addition of increasing volumes of serum did not influence the CSF-A beta 42 levels. Our findings suggest that the reduction in CSF-A beta 42 found in bacterial meningitis is not a direct consequence of the inflammatory process. The cause may be disturbance of the clearance of A beta 42 from the brain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11698140     DOI: 10.1016/s0304-3940(01)02285-6

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  24 in total

1.  Amyloid and tau cerebrospinal fluid biomarkers in HIV infection.

Authors:  Magnus Gisslén; Jan Krut; Ulf Andreasson; Kaj Blennow; Paola Cinque; Bruce J Brew; Serena Spudich; Lars Hagberg; Lars Rosengren; Richard W Price; Henrik Zetterberg
Journal:  BMC Neurol       Date:  2009-12-22       Impact factor: 2.474

Review 2.  Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease.

Authors:  Kaj Blennow; Bruno Dubois; Anne M Fagan; Piotr Lewczuk; Mony J de Leon; Harald Hampel
Journal:  Alzheimers Dement       Date:  2014-05-03       Impact factor: 21.566

3.  Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections.

Authors:  Jan Jessen Krut; Henrik Zetterberg; Kaj Blennow; Paola Cinque; Lars Hagberg; Richard W Price; Marie Studahl; Magnus Gisslén
Journal:  J Neurol       Date:  2012-10-09       Impact factor: 4.849

Review 4.  Neurochemical dementia diagnostics: assays in CSF and blood.

Authors:  Piotr Lewczuk; Joachim Hornegger; Rüdiger Zimmermann; Markus Otto; Jens Wiltfang; Johannes Kornhuber
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

5.  A proteomic approach for the diagnosis of bacterial meningitis.

Authors:  Sarah Jesse; Petra Steinacker; Stefan Lehnert; Martin Sdzuj; Lukas Cepek; Hayrettin Tumani; Olaf Jahn; Holger Schmidt; Markus Otto
Journal:  PLoS One       Date:  2010-04-08       Impact factor: 3.240

6.  Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism.

Authors:  Niklas Mattsson; Daniel Bremell; Rolf Anckarsäter; Kaj Blennow; Henrik Anckarsäter; Henrik Zetterberg; Lars Hagberg
Journal:  BMC Neurol       Date:  2010-06-22       Impact factor: 2.474

7.  Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid.

Authors:  Maria Bjerke; Erik Portelius; Lennart Minthon; Anders Wallin; Henrik Anckarsäter; Rolf Anckarsäter; Niels Andreasen; Henrik Zetterberg; Ulf Andreasson; Kaj Blennow
Journal:  Int J Alzheimers Dis       Date:  2010-07-15

Review 8.  Protein-based biomarkers in cerebrospinal fluid and blood for Alzheimer's disease.

Authors:  Yongyao Fu; Deming Zhao; Lifeng Yang
Journal:  J Mol Neurosci       Date:  2014-06-25       Impact factor: 3.444

Review 9.  Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Authors:  Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber
Journal:  World J Biol Psychiatry       Date:  2017-10-27       Impact factor: 4.132

Review 10.  CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease.

Authors:  K Blennow; E Vanmechelen; H Hampel
Journal:  Mol Neurobiol       Date:  2001 Aug-Dec       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.